CRISPR Therapeutics AG recently reported its fourth-quarter and full-year 2025 results, showing revenue falling to US$0.864 million in Q4 and US$3.51 million for the year, alongside wider net losses ...

Scientists have developed a powerful new sensor that uses light to detect extremely tiny signs of cancer in the blood, raising hopes for earlier diagnosis through a simple blood test. The technology ...

The sensor combines nanostructures made of DNA with quantum dots and CRISPR gene editing technology to detect biomarkers, ...

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.

A sales partner offered a ray of hope that this company couldn't for itself.

The Olympic Games have always been a proving ground for human excellence, but in the modern era, they’re also a showcase for technological innovation. From high-definition cameras and advanced sensors ...

During her postdoctoral fellowship at Harvard’s Wyss Institute, Professor Nicole Weckman (ISTEP, ChemE) developed a new technique to rapidly detect antimicrobial resistant genes in a pathogenic fungus ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...

Koo joins from South Korean firm Yulchon, where he was a partner. At ToolGen he will help lead the company’s efforts to monetise its IP portfolio through royalty income. He will work alongside ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

Louis was the first patient at Children's Hospital of Philadelphia — outside of a clinical trial — to get a new FDA-approved treatment. It involves collecting his stem cells, which are then ...